Peanut Allergy R&D Pipeline Analysis Report, H2-2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
31
Peanut Allergy R&D Pipeline Analysis Report, H2-2018

Dublin, Jan. 18, 2019 (GLOBE NEWSWIRE) -- The "Peanut Allergy R&D Pipeline Analysis Report, H2-2018" report has been added to ResearchAndMarkets.com's offering. The Peanut Allergy pipeline guide presents complete overview of drugs currently being developed for Peanut Allergy. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Peanut Allergy pipeline candidate. Research and Development progress along with latest news related to each of the Peanut Allergy pipeline candidates is included. Major companies participating in therapeutic development of Peanut Allergy are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided. Amid strong interest for cure of Peanut Allergy from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Peanut Allergy clinical and pre clinical products. The report assists in identifying potential upcoming companies and drugs in Peanut Allergy pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition. Scope of Peanut Allergy pipeline report includes

  • Panorama of Peanut Allergy pipeline markets including statistics on therapeutic drugs and companies involved
  • Peanut Allergy Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Peanut Allergy pipeline candidates across various Mechanism of Actions' are also presented in the study
  • Overview of companies participating in Peanut Allergy pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Peanut Allergy pipeline therapeutics

Key Topics Covered: I. Key Findings 1. Companies Investing in Peanut Allergy Pipeline include Number of Companies with Peanut Allergy projects in pre clinical Development Number of Companies with Peanut Allergy projects in Clinical Development Peanut Allergy Pipeline Companies based in Americas Peanut Allergy Pipeline Companies based in Europe Peanut Allergy Pipeline Companies based in Asia Pacific Peanut Allergy Pipeline Companies based in Rest of the World 2. Pipeline Candidates include Peanut Allergy Pipeline Agents in pre clinical/ Discovery stage of Development Peanut Allergy Pipeline Agents in Clinical Development stage Peanut Allergy Pipeline Therapeutic Compounds received special status Mechanism of Action of most pipeline Drugs Small molecules among the Peanut Allergy Pipeline agents II. Insights into Peanut Allergy Pipeline - 1. Disease Overview Introduction to Peanut Allergy Symptoms and Causes of Peanut Allergy Treatment or Prevention Options for Peanut Allergy Other Details 2. Phase wise Pipeline Compounds Peanut Allergy Pipeline Pre Clinical/ Discovery stage Drugs Peanut Allergy Pipeline Phase 1 stage Drugs Peanut Allergy Pipeline Phase 2 stage Drugs Peanut Allergy Pipeline Phase 3 stage Drugs Peanut Allergy Pipeline Pre Registration stage Drugs 3. Company wise Peanut Allergy Pipeline Compounds 4. Peanut Allergy Pipeline by Mechanism of Action III. Peanut Allergy Pipeline Compound Details Drug Details 1. Snapshot Name of the Therapeutic Agent Originator Developing Company Co Developer/ License Partner Orphan Drug / Fast Track/ Designation Development Phase 2. Drug Overview 3. Mechanism of Action 4. Current Status 5. Clinical Trial Details IV. Peanut Allergy Pipeline Company Briefs V. Latest News and Developments in Global Peanut Allergy Pipeline Market VI. Appendix For more information about this report visit https://www.researchandmarkets.com/research/w...lergy?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Allergy Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insurance Bad Faith: Navigating California's Rigorous Laws

Updated Category News Views 6

Understanding What Constitutes Bad Faith Insurance What does it really mean when an insurer acts in "bad faith"? Well, the legal standard doesn't leave much wiggle room in California. These aren't just bad outcomes; we're talking about conduct that defies what's reasonable under state law. Demián I. Oksenendler, a seasoned bad faith attorney, shed some light on this in a...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 0

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 0

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading
QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 0

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 7

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 0

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading
Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Updated Category News Views 8

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 5

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
High-Grade Copper Spurs Optimism for PolarX in Alaska

Updated Category News Views 0

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Continue Reading

Top 5 Most Recently Viewed Articles

Promoting Mental Wellness in Athletics: A Collaborative Effort

Updated Category News Views 403

Athlete Mental Health Week: A Collaborative Initiative The upcoming Athlete Mental Health Week (AMHW) is set to take place soon, bringing together several nonprofit organizations dedicated to improving mental health awareness among athletes. This year's participants include Hilinski's Hope Foundation, Athletes for Hope, the Kevin Love Fund, and the Sarah Shulze...

Continue Reading
Pulnovo Medical Secures New Funding to Boost Global Growth

Updated Category News Views 243

Pulnovo Medical Announces New Investment to Expand Global Reach Pulnovo Medical, a renowned pioneer in medical devices focused on pulmonary hypertension and heart failure, has secured a new investment from EQT Group, a prominent global private equity firm. This partnership symbolizes an exciting new chapter for the company, which continues to receive unwavering support...

Continue Reading
Exciting News: The New Racing Prodigy Series Takes Off This Year

Updated Category News Views 246

Racing Prodigy™ Launches Innovative Racing Series Racing Prodigy™ is set to shake up the motorsports world by introducing an exciting gaming-to-real-life racing series. This series not only redefines the way fans can interact with motorsports but also aims to increase accessibility in competitive racing. Transforming Passion into Reality The concept behind this...

Continue Reading
Mega Matrix's FlexTV Streams a New Sports Drama

Updated Category News Views 11

A Fresh Twist in Sports Dramas Drama, sports, and comeback stories are like peanut butter and jelly—each one complements the other perfectly. Now, Mega Matrix Inc. is jumping into the arena with their new short-drama series, From NBA Dropout to Tennis Ace, streaming on their platform, FlexTV. Throw aside any expectations of typical sports films because this one's not...

Continue Reading
EPAM Systems Achieves Top IT Vendor Status for 2025 in Europe

Updated Category News Views 441

EPAM Systems Recognized as a Leading IT Vendor in Europe EPAM Systems, Inc. (NYSE: EPAM), a prominent name in digital transformation services and product engineering, has achieved remarkable recognition as a top IT vendor in Europe for 2025. This accolade is particularly noteworthy as it marks the second consecutive year in which EPAM has earned this honor, as evidenced...

Continue Reading